indazoles has been researched along with ADPKD in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calvet, JP; Georg, GI; Jakkaraj, SR; Li, X; Magenheimer, BS; Reif, GA; Sundar, SV; Tash, JS; Wallace, DP; Yu, ASL; Zhou, JX | 1 |
| Golemis, EA; Pirestani, S | 1 |
| Gao, L; Guo, D; Jiang, H; Kan, W; Li, J; Li, N; Liu, T; Xiong, B; Yang, B; Yuan, H; Zhang, H; Zhao, D; Zhou, Y | 1 |
| Buelli, S; Corna, D; Guglielmotti, A; Locatelli, M; Morigi, M; Perico, N; Pezzotta, A; Remuzzi, A; Remuzzi, G; Rottoli, D; Zanchi, C; Zoja, C | 1 |
| Steinman, TI | 1 |
1 review(s) available for indazoles and ADPKD
| Article | Year |
|---|---|
Polycystic kidney disease: a 2011 update.
Topics: Antineoplastic Agents; Benzazepines; Curcumin; Everolimus; Gastrointestinal Agents; Glomerular Filtration Rate; Humans; Hypertension; Hypoglycemic Agents; Immunosuppressive Agents; Indazoles; Kidney; Metformin; Octreotide; Organ Size; Polycystic Kidney, Autosomal Dominant; Sirolimus; Sodium; Tolvaptan | 2012 |
4 other study(ies) available for indazoles and ADPKD
| Article | Year |
|---|---|
The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease.
Topics: Actins; Animals; Carboxylic Acids; Cell Proliferation; Cells, Cultured; Colforsin; Cyclin-Dependent Kinase 4; Cystic Fibrosis Transmembrane Conductance Regulator; Cysts; EGF Family of Proteins; Heat-Shock Proteins; Humans; Indazoles; Kidney; Mice; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Proto-Oncogene Proteins c-akt; Receptors, Cell Surface | 2022 |
H2-gamendazole: a new therapeutic lead for the treatment of polycystic kidney disease.
Topics: Humans; Indazoles; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant | 2022 |
Discovery of Novel
Topics: Animals; Cyclin-Dependent Kinases; Cysts; Dogs; Indazoles; Mice; Polycystic Kidney, Autosomal Dominant | 2022 |
Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease.
Topics: Animals; Chemokine CCL2; Disease Models, Animal; In Vitro Techniques; Indazoles; Macrophages; Male; Monocytes; Podocytes; Polycystic Kidney, Autosomal Dominant; Propionates; Proteinuria; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; RNA, Messenger | 2015 |